Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript
Perfect. Hello, everyone. Good afternoon. This is Rachel Vatnsdal Olson with the life science tools and diagnostics team here at JPMorgan. I'm joined by Paul Diaz, CEO of Myriad here. And so this will be a 40-minute session, roughly 20, 25 minutes of our presentation followed by Q&A.
And so with that, I'll pass it over to you.
Thanks, Rachel. Great to be here, and thank you all for attending late in the day. I'm sure it's been a long day for everyone. Really excited to present and give you an update on the progress that we're making at Myriad Genetics. It's been a busy but good year for us. And so we'll dive in. And again, we'll have some time for questions as I doubt I will take more than 25 minutes. So thanks again for your participation.
For those of you participating online, we encourage you to look at the presentation. And at the end, we will give some reconciliations in terms of our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |